Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2001, the company has made significant strides in developing innovative therapies for rare diseases, particularly in the field of metabolic disorders. Savient is best known for its flagship product, Krystexxa, which offers a unique treatment option for chronic gout, setting it apart in a competitive market. With a focus on research and development, Savient has established a strong market position, catering to patients with unmet medical needs. The company operates primarily in North America, with a commitment to advancing healthcare solutions that improve patient outcomes. Through its dedication to innovation and quality, Savient Pharmaceuticals continues to make a meaningful impact in the biopharmaceutical landscape.
DitchCarbon Score
How does Savient Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Savient Pharmaceuticals, Inc.'s score of 28 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Savient Pharmaceuticals, Inc.'s reported carbon emissions
Savient Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Savient Pharmaceuticals may not have established formal commitments to address carbon emissions or climate change initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it remains essential for companies like Savient to consider developing and communicating their climate strategies to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Savient Pharmaceuticals, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
